EUVIMEDObjevte EUVIMED
Open access

Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing

Matthew H Mossayebi iD, Sophie J Adams iD, Megan E Bunnell iD, Stephanie H Guseh iD, Louise E Wilkins-Haug iD

Prenatal Diagnosis · 2026

DOI: 10.1002/pd.70182 ↗

At a glance

Journal article in Prenatal Diagnosis, 2026. Written by Matthew H Mossayebi and 4 co-authors. Institution: Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts, USA. Major MEDLINE topics: Fetal Growth Retardation, Genetic Testing. 35 references. The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objectives

We evaluated the diagnostic yield of karyotype (KT) and chromosomal microarray (CMA) with isolated severe FGR diagnosed before 32 weeks' gestation. Exome and genome sequencing (ES/GS) level data were available in a subset of this population.

Method

We performed a retrospective review of singleton pregnancies (delivered 2022–2025) with estimated fetal weight or abdominal circumference < 3rd percentile before 32 weeks' gestation, no sonographic structural anomalies, and diagnostic testing (KT, CMA, ES, or GS) via amniocentesis or cord blood. Cases with abnormal cell‐free DNA were excluded.

Results

Forty cases were included (mean diagnosis 26.8 weeks). Testing was performed via amniocentesis in 42% and cord blood in 58%. All KT (27/40) were normal. CMA (39/40) identified one pathogenic CNV (2.5%) and three (7.5%) variants of uncertain significance (VUS). Four (10%) showed ≥ 1 region of absence of heterozygosity (AOH) > 10Mb; one revealed maternal uniparental disomy of chromosome 6. Sequencing ( N = 10) detected one VUS in COL1A1 . Acute viral infection was not observed in any of the cases.

Conclusions

CMA was diagnostic in 2/39 (5.1%) cases, a pathogenic CNV implicating the SHOX gene, and maternal UPD 6, which were consistent with FGR. There was a remarkable rate (10%) of AOH. Further investigation, including placental studies and genome sequencing, may elucidate whether AOH is a contributing factor for FGR.

Subjects

MeSH terms (MEDLINE)

Fetal Growth RetardationGenetic TestingHumansFemalePregnancyRetrospective StudiesAdultKaryotypingAmniocentesisPrenatal DiagnosisInfant, NewbornGestational Age

Authors and institutions

  • Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID profiles: Matthew H Mossayebi, Sophie J Adams, Megan E Bunnell, Stephanie H Guseh, Louise E Wilkins-Haug

Cite

APA

Mossayebi, M. H., Adams, S. J., Bunnell, M. E., Guseh, S. H., & Wilkins-Haug, L. E. (2026). Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing. Prenatal Diagnosis. https://doi.org/10.1002/pd.70182

Vancouver

Mossayebi MH, Adams SJ, Bunnell ME, Guseh SH, Wilkins-Haug LE. Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing. Prenatal Diagnosis. 2026. doi:10.1002/pd.70182

BibTeX
@article{Mossayebi2026,
  author = {Mossayebi, Matthew H and Adams, Sophie J and Bunnell, Megan E and Guseh, Stephanie H and Wilkins-Haug, Louise E},
  title = {Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing},
  journal = {Prenatal Diagnosis},
  year = {2026},
  doi = {10.1002/pd.70182}
}
Start for free →